※手術後に免疫細胞治療を行うことで再発が減少し、生存率が高まったという結果が、海外の権威ある学術誌に報告(Cancer Immunol Immunother(2014)、Lancet(2000)、Cancer(1997))されています。(※)
(※)・『Cancer Immunol Immunother』 Kimura H, Matsui Y, Ishikawa A, Nakajima T, Yoshino M, Sakairi Y.Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with r esected primary lung cancer. Cancer Immunol Immunother. Epub 20 14 Sep 28.
・『Lancet』 Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T., Adoptive immunotherapy to lower postsurgical recurrence rates of hepatoc ellular carcinoma: a randomised trial., Lancet. 356(9232):802-7, 2000.
・『Cancer』 Kimura H, Yamaguchi Y., A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer. 80(1):42-9, 1997